Shanghai China and Rockville Maryland – August 18, 2014 BHC Center of Financial & Investment Business (“BHC”), an Atlanta based affiliate of Bao Hao Investment Management Co., Ltd. of Shanghai, has announced the first of what it expects to be several equity investments in 20/20 GeneSystems, Inc. (“20/20”). In making the investment BHC is seeking to help advance the introduction in China of 20/20’s blood test for the early detection of lung cancer (see

20/20 currently produces and markets this innovative blood test for the early detection of lung cancer in the United States. Primary care physicians employ the blood test to help detect lung cancer in patients who are smokers and former smokers. It is known as “PAULAs test.”

The smoking rate in China far exceeds that of the U.S. as over half of Chinese men smoke according to the World Health Organization. That trend, coupled with air pollution in the urban areas, contributes to very high incidences of lung cancer in China.

“There is a great unmet need for improved early lung cancer detection in China” said Hao Xu, Chairman of BHC China. “BHC has confidence in the further development of 20/20 and its PAULA blood test because 20/20 has a management team with deep understanding and strong insights into the market and an excellent scientific research team as well” Xu said.

“We appreciate the confidence of BHC China and look forward to partnering with them as we introduce our lifesaving diagnostic products into China,” stated Jonathan Cohen, CEO of 20/20. “This blood test for early detection of lung cancer, along with other products in development, can improve outcomes for cancer patients. BHC China shares our vision and we welcome this new partnership” Cohen said.

About BHC China Bao Hao Investment Management Co., Ltd. (, founded in 2000, provides professional services to address the financing needs of various enterprises. Its limited partners include the owners of major hospitals and healthcare companies in fields such as pharmaceuticals, chemical reagents, and medical equipment.

About 20/20 GeneSystems, Inc. 20/20 GeneSystems, Inc. ( develops and commercializes innovative tests that aid in the early detection and therapy selection for various types of cancers. The Company is now marketing its blood test for the early detection of lung cancer through its Genesys BioLabs business unit. 20/20 also has a patent technology for multiplex biomarker measurement in solid tumors that is being used to develop companion diagnostics for personalized medicine. Contact: Careen Carlton— 240-453-6339 x108